Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

Primary Objective: To determine the safety, tolerability, maximum tolerated dose (MTD) and administration schedule, and optimal cell dose (OCD) and schedule of CAR.TROP2/IL15-transduced / TGFBR2KO CB-NK cells \[TRICK-NK - TROP2-targeted, Reprogrammed with IL-15, CBderived, Knockout (TGFBR2) NK\] + T-Dxd, in T-Dxd eligible HER2 positive and HER2 low advanced breast cancers. Secondary Objectives: To determine the antitumor activity of TRICK-NK + T-Dxd combination The intent of offering this treatment is to provide a possible therapeutic benefit and thus, the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability.